|
|
|
|
|||||
|
|
|
It agreed to be acquired by a high-profile pharmaceutical company.
The buyout could be worth as much as $5.2 billion.
One of the best catalysts for sudden, sharp rise in the price of a stock is when the company behind it get acquired at a premium. Case in point: Akero Therapeutics (NASDAQ: AKRO), whose shares soared by more than 16% Thursday after it was revealed the biotech will have a new owner. That pop was especially impressive, given that the bellwether S&P 500 (SNPINDEX: ^GSPC) slumped by 0.3% on the day.
Akero's buyer is none other than Novo Nordisk, the Denmark-based pharmaceutical company behind star weight loss drug Wegovy.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Image source: Getty Images.
In separate press releases, Novo Nordisk and Akero wrote that they have signed a definitive agreement for the former to purchase the latter in an all-cash deal. Akero stockholders are to receive $54 per share in cash, plus a nontransferable contingent value right (CVR).
One CVR will grant the holder an additional $6 per-share contingent -- hence the name -- on Akero's investigational efruxifermin drug, obtaining U.S. Food and Drug Administration (FDA) approval by June 30, 2031. The drug targets a stage of cirrhosis arising from the liver disease metabolic dysfunction-associated steatohepatitis (MASH).
All told, the deal will be worth as much as $5.2 billion. It has been unanimously approved by Akero's boards of directors, and is expected to close around New Year's.
In its press release on the buyout, Novo Nordisk quoted chief scientific officer Martin Lange as saying that it "complements Novo Nordisk's leading portfolio and is aligned with our commitment to building a competitive portfolio of treatment options across the stages of MASH."
Before you buy stock in Akero Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Akero Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $654,835!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,159,218!*
Now, it’s worth noting Stock Advisor’s total average return is 1,081% — a market-crushing outperformance compared to 192% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
*Stock Advisor returns as of October 7, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
| Oct-30 | |
| Oct-29 | |
| Oct-13 | |
| Oct-10 | |
| Oct-10 | |
| Oct-10 | |
| Oct-10 | |
| Oct-10 | |
| Oct-10 | |
| Oct-09 | |
| Oct-09 | |
| Oct-09 | |
| Oct-09 | |
| Oct-09 | |
| Oct-09 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite